Last updated: September 7, 2026
DARZALEX, the daratumumab biologic marketed by Johnson & Johnson through Janssen, has become one of the largest products in multiple myeloma. Global sales increased from approximately $4.2 billion in 2020 to $11.7 billion in 2024. Growth has been driven by earlier-line use, combination regimens, and the subcutaneous DARZALEX FASPRO formulation. The product remains protected by biologic exclusivity through November 2027, while formulation, method-of-use, and manufacturing patents may extend commercial protection into the 2030s.
How much revenue does DARZALEX generate?
DARZALEX generated approximately $11.7 billion in worldwide sales in 2024, according to Johnson & Johnson reporting. It was one of the company’s largest pharmaceutical products and a major contributor to its oncology portfolio.
| Fiscal year |
DARZALEX worldwide sales |
Year-over-year growth |
| 2020 |
$4.2 billion |
Approximately 31% |
| 2021 |
$6.0 billion |
Approximately 44% |
| 2022 |
$8.0 billion |
Approximately 32% |
| 2023 |
$9.7 billion |
Approximately 22% |
| 2024 |
$11.7 billion |
Approximately 20% |
Sources: Johnson & Johnson annual reports and fourth-quarter earnings releases.[1-5]
The five-year increase represents a compound annual growth rate of approximately 29%. Growth remained strong despite the maturity of the multiple myeloma market because DARZALEX expanded from later-line treatment into newly diagnosed disease and became embedded in standard combination regimens.
What is driving DARZALEX revenue growth?
The principal revenue drivers are:
- Earlier-line treatment in newly diagnosed multiple myeloma.
- Increased use of quadruplet regimens containing daratumumab.
- Conversion from intravenous DARZALEX to subcutaneous DARZALEX FASPRO.
- Continued treatment of relapsed and refractory patients.
- Expansion across transplant-eligible and transplant-ineligible populations.
- Combination use with proteasome inhibitors, immunomodulatory drugs, and corticosteroids.
Daratumumab targets CD38, a protein expressed on malignant plasma cells. Its clinical utility across multiple treatment lines has allowed Janssen to retain patients as they move through the treatment pathway.
Why is DARZALEX FASPRO important to the commercial outlook?
DARZALEX FASPRO is the subcutaneous formulation of daratumumab combined with recombinant human hyaluronidase-fihj. It was approved by the FDA in May 2020.[6] Administration is substantially faster than the original intravenous formulation, reducing chair time and improving infusion-center capacity.
The subcutaneous formulation has four commercial effects:
- It improves treatment convenience for patients and providers.
- It lowers administration burden.
- It supports use in community oncology practices.
- It creates additional formulation and delivery-system patent protection.
The formulation also reduces the operational disadvantages of intravenous antibody treatment. Janssen has marketed FASPRO across an expanding range of indications, making it the main commercial vehicle for future DARZALEX use.
How does DARZALEX compare with intravenous daratumumab?
| Attribute |
DARZALEX intravenous |
DARZALEX FASPRO |
| Active antibody |
Daratumumab |
Daratumumab |
| Delivery |
Intravenous infusion |
Subcutaneous injection |
| Administration burden |
Higher |
Lower |
| FDA approval |
2015 |
2020 |
| Commercial role |
Original formulation |
Primary growth formulation |
| IP profile |
Core antibody and use patents |
Formulation, delivery, and use patents |
The shift to FASPRO also provides lifecycle management. Even if a competitor eventually develops a biosimilar or interchangeable product to the reference antibody, patents directed to the subcutaneous combination, dosing schedules, and administration technology may remain relevant.
What FDA approvals support the DARZALEX market?
DARZALEX was first approved by the FDA in November 2015 for patients with multiple myeloma who had received at least three prior lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory agent.[7]
Subsequent approvals expanded the product into combination and earlier-line treatment.
| FDA milestone |
Commercial significance |
| November 2015 initial approval |
Established daratumumab in heavily pretreated multiple myeloma |
| 2016-2017 combination approvals |
Expanded use with lenalidomide, dexamethasone, bortezomib, and other backbones |
| 2019 approval in newly diagnosed transplant-eligible disease |
Moved DARZALEX into first-line treatment |
| 2020 DARZALEX FASPRO approval |
Reduced administration burden and strengthened lifecycle protection |
| 2021-2022 expanded first-line and relapsed-disease uses |
Increased treatment-line penetration |
| 2024 D-VRd approval in newly diagnosed transplant-eligible disease |
Reinforced quadruplet therapy as a major growth segment |
The 2024 FDA approval of DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem-cell transplant expanded the product’s role in frontline treatment.[8]
The market value of this expansion is higher than the incremental number of approved indications suggests. First-line treatment generates longer treatment duration, earlier physician familiarity, and greater potential for continued use in later lines.
When does DARZALEX lose exclusivity?
DARZALEX has several different exclusivity dates because FDA regulatory exclusivity, patent protection, and commercial protection are separate concepts.
| Protection category |
Key date or period |
Effect |
| Orphan-drug exclusivity |
Seven years from applicable orphan approval |
Prevented approval of the same drug for the same orphan indication during the exclusivity period |
| Biologic reference-product exclusivity |
Through approximately November 2027 |
Prevents FDA approval of a biosimilar before the 12-year period expires |
| Core antibody patents |
Patent-specific dates, generally extending beyond regulatory exclusivity |
Can delay biosimilar or competing antibody commercialization |
| FASPRO formulation and delivery patents |
Patent-specific dates that may extend into the 2030s |
Protect the subcutaneous product and administration method |
| Method-of-use patents |
Patent-specific dates |
Cover treatment combinations, patient populations, and dosing regimens |
The 12-year U.S. reference-product exclusivity period runs from the date of first licensure under the Public Health Service Act. DARZALEX was first approved on November 16, 2015, placing the end of the statutory reference-product exclusivity period in November 2027.[7,9]
A biosimilar application could be submitted before the end of that period, but FDA approval could not take effect until the exclusivity period expires. Commercial launch would still depend on patent outcomes, settlements, and the scope of any granted biosimilar license.
What is the patent expiration date for DARZALEX?
There is no single DARZALEX patent expiration date. The protection package includes patents covering:
- Daratumumab antibodies and antibody sequences.
- CD38 binding and therapeutic use.
- Combination treatment with standard multiple myeloma agents.
- Subcutaneous formulations.
- Recombinant human hyaluronidase combinations.
- Dosing schedules and administration methods.
- Manufacturing and production processes.
The core commercial question is not the expiry of the earliest antibody patent. It is whether later patents covering FASPRO, dosing, combinations, and administration can prevent a commercially meaningful competing product.
U.S. patent term adjustment, terminal disclaimers, patent-term extension, patent-family prosecution, and claim scope affect the operative expiration dates. The relevant patent portfolio must therefore be analyzed claim by claim rather than reduced to one date.
What is the Orange Book status of DARZALEX?
DARZALEX is a biologic licensed under the Public Health Service Act. Its reference-product and biosimilar information is tracked primarily through the FDA Purple Book rather than the Orange Book.[9]
The Orange Book is principally used for small-molecule drugs approved under the Federal Food, Drug, and Cosmetic Act. It records patents and exclusivity for many small-molecule products, while biologic competition is governed through the Biologics Price Competition and Innovation Act framework.
For DARZALEX, the key regulatory records are:
- FDA biologics license approval.
- Purple Book reference-product status.
- FDA biosimilar application and approval records.
- Patent litigation under the BPCIA.
- Public patent and licensing records.
This distinction matters because the absence of an Orange Book listing does not mean that DARZALEX lacks patent protection.
Which companies are challenging DARZALEX exclusivity?
No U.S.-approved daratumumab biosimilar was publicly recorded through the end of 2024. The likely competitive field includes major biologics manufacturers with oncology portfolios, antibody manufacturing capacity, and established regulatory infrastructure.
Potential participants include:
- Sandoz.
- Biocon Biologics.
- Celltrion.
- Samsung Bioepis.
- Amgen.
- Fresenius Kabi.
- Pfizer.
- Teva.
- Coherus BioSciences.
- Large Chinese biologics manufacturers seeking U.S. or European entry.
A biosimilar challenger would need to demonstrate high similarity to daratumumab, including analytical comparability, pharmacokinetics, immunogenicity, and, depending on the regulatory strategy, comparative clinical evidence. The product’s extensive combination use creates additional commercial complexity because approval of the antibody does not automatically eliminate method-of-use patent risk.
What generic entry risks exist for DARZALEX?
Traditional generic entry is not applicable to daratumumab. The relevant risk is biosimilar or follow-on biologic entry.
The most likely sequence is:
- Biosimilar filing after or near the end of the 12-year exclusivity period.
- Patent notice and BPCIA litigation.
- Settlement or negotiated launch date.
- Initial entry in selected markets.
- Price pressure in hospital and payer channels.
- Gradual substitution or contracting pressure on FASPRO.
The commercial impact could be slower than the impact of a small-molecule generic because biologic substitution depends on interchangeability, payer policy, physician behavior, site-of-care economics, and the availability of competing formulations.
How strong is the DARZALEX patent estate?
The DARZALEX patent estate is commercially strong because it combines product, formulation, use, and delivery protection.
Core antibody protection
Core patents protect the daratumumab molecule and its binding characteristics. These patents provide the foundation for the product but are generally the first layer to face expiration or invalidity challenges.
Formulation protection
FASPRO adds protection directed to the combination of daratumumab with recombinant human hyaluronidase-fihj and to the subcutaneous administration method. These patents are strategically important because FASPRO is the dominant lifecycle formulation.
Method-of-use protection
Method patents cover treatment of multiple myeloma in defined patient groups and in combination with agents such as:
- Lenalidomide.
- Bortezomib.
- Carfilzomib.
- Pomalidomide.
- Dexamethasone.
- Stem-cell transplantation protocols.
Method-of-use patents can limit the commercial use of a biosimilar even when the biosimilar sponsor obtains approval for a narrower label.
Manufacturing protection
Manufacturing patents can cover cell lines, purification, formulation, stability, and production processes. These patents are less visible to prescribers but can increase the cost and timing risk of biosimilar development.
Overall, the estate is stronger than a single-molecule patent portfolio because a challenger must evaluate multiple layers of potential infringement. The principal weakness is that method-of-use patents can be designed around or avoided through label carving, while antibody and formulation patents face validity and written-description challenges.
What patent litigation affects DARZALEX?
The principal litigation risk is expected to arise under the BPCIA once a biosimilar sponsor files an application and provides the required patent information. Litigation could involve:
- Core daratumumab composition patents.
- FASPRO formulation patents.
- Hyaluronidase combination claims.
- Dosing and administration claims.
- Manufacturing patents.
- Patent-term and validity disputes.
Through the end of 2024, the market had not experienced a U.S. biosimilar launch that established a settled commercial entry date for daratumumab. The absence of an approved biosimilar preserved Janssen’s pricing and contracting position.
A settlement could permit entry before the final expiration of every asserted patent. The most commercially important settlement term would be the launch date, followed by whether the challenger could market a subcutaneous product or only an intravenous formulation.
How does DARZALEX compare with competing multiple myeloma drugs?
DARZALEX competes across several classes rather than against one direct substitute.
| Product or class |
Company |
Competitive position |
| SARCLISA, isatuximab |
Sanofi |
Direct anti-CD38 antibody competitor |
| Empliciti, elotuzumab |
Bristol Myers Squibb |
Earlier antibody-based competitor with a smaller commercial position |
| Revlimid, lenalidomide |
Bristol Myers Squibb |
Foundational backbone, increasingly generic |
| Kyprolis, carfilzomib |
Amgen |
Proteasome inhibitor used in combination regimens |
| CAR-T therapies |
Bristol Myers Squibb, Johnson & Johnson, others |
High-intensity treatment for eligible relapsed patients |
| Bispecific antibodies |
Johnson & Johnson, AbbVie, Roche, others |
Rapidly expanding later-line and potentially earlier-line competition |
| Stem-cell transplant |
Multiple providers |
Treatment pathway rather than a competing branded drug |
The most important direct antibody competitor is SARCLISA. DARZALEX has a substantial first-mover and clinical-evidence advantage, broader line-of-therapy penetration, and a larger installed treatment base.
The more significant long-term threat is not necessarily another anti-CD38 antibody. It is the movement of bispecific antibodies and CAR-T therapies into earlier treatment lines, where they could reduce the duration or sequencing value of standard daratumumab-based regimens.
What licensing deals support DARZALEX economics?
Genmab discovered daratumumab and licensed commercial rights to Janssen in 2012. The agreement provided Genmab with an upfront payment, milestone opportunities, and royalties on net sales.[10]
The arrangement is economically important because DARZALEX sales generate value for both parties:
- Janssen controls global development, manufacturing, commercialization, and regulatory strategy.
- Genmab receives royalty income without bearing the full cost of global commercialization.
- Johnson & Johnson retains a strategic oncology asset.
- Genmab has an incentive to support continued label expansion and lifecycle development.
The royalty structure reduces Johnson & Johnson’s net margin relative to a wholly owned product, but the arrangement provided access to a commercially validated antibody without internal discovery risk.
What is the DARZALEX financial trajectory through 2030?
DARZALEX should continue generating substantial revenue after 2027, but annual growth is likely to slow as the product approaches biosimilar exposure and as multiple myeloma treatment becomes more competitive.
| Period |
Expected commercial dynamic |
| 2025-2026 |
Continued growth from frontline quadruplets, FASPRO adoption, and geographic expansion |
| 2027 |
Statutory biologic exclusivity expires; biosimilar filings and patent litigation become more relevant |
| 2028-2029 |
Potential first biosimilar settlements or launches, depending on patent outcomes |
| 2030 onward |
Greater price pressure, payer substitution, and competition from bispecifics and CAR-T therapies |
Revenue durability will depend on five variables:
- The speed of frontline adoption.
- FASPRO retention relative to future biosimilar formulations.
- Patent settlement timing.
- The extent of biosimilar substitution.
- Competition from newer immunotherapies.
The product’s high revenue base creates meaningful downside exposure if biosimilar entry occurs rapidly. A 20% decline from 2024 sales would represent approximately $2.3 billion in annual revenue. A 40% decline would represent approximately $4.7 billion. These figures illustrate the financial significance of patent and formulation protection to Johnson & Johnson and Genmab.
Key Takeaways
- DARZALEX sales reached approximately $11.7 billion in 2024.
- Revenue increased at an estimated 29% compound annual rate from 2020 through 2024.
- DARZALEX FASPRO is the central lifecycle and commercial-growth product.
- The FDA granted first approval in November 2015, placing 12-year reference-product exclusivity through approximately November 2027.
- DARZALEX is governed primarily by the Purple Book and BPCIA framework, not the Orange Book.
- No U.S.-approved daratumumab biosimilar was publicly recorded through the end of 2024.
- Patent protection extends beyond the core antibody to formulation, administration, treatment combinations, dosing, and manufacturing.
- The principal long-term threats are biosimilar entry, FASPRO substitution, bispecific antibodies, and CAR-T therapies.
- The revenue base is large enough that even moderate post-exclusivity erosion would materially affect Johnson & Johnson and Genmab.
FAQs About DARZALEX Market and Patent Exposure
What is the active ingredient in DARZALEX?
The active ingredient is daratumumab, a fully human monoclonal antibody targeting CD38 on malignant plasma cells.
Is DARZALEX a biologic or a generic drug?
DARZALEX is a biologic licensed under the Public Health Service Act. A competing product would generally be a biosimilar, not a conventional generic.
Does DARZALEX have orphan-drug exclusivity?
Yes. Certain multiple myeloma indications received orphan-drug exclusivity. The duration is seven years from the relevant approval, separate from patent protection and the 12-year reference-product exclusivity period.
Can a biosimilar copy DARZALEX FASPRO?
A biosimilar sponsor can seek approval for a daratumumab product, but the subcutaneous FASPRO formulation may face separate formulation, delivery, and method-of-use patent claims.
Why does DARZALEX remain commercially important after patent expiry?
Daratumumab is embedded in treatment guidelines, combination regimens, and physician practice. Clinical familiarity, treatment-line expansion, and FASPRO administration advantages can preserve revenue after regulatory exclusivity ends, although biosimilar competition would increase pricing pressure.
References
- Johnson & Johnson. (2021). 2020 annual report.
- Johnson & Johnson. (2022). 2021 annual report.
- Johnson & Johnson. (2023). 2022 annual report.
- Johnson & Johnson. (2024). 2023 annual report.
- Johnson & Johnson. (2025). 2024 annual report.
- U.S. Food and Drug Administration. (2020). FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma.
- U.S. Food and Drug Administration. (2015). FDA approves Darzalex for multiple myeloma.
- U.S. Food and Drug Administration. (2024). FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Genmab A/S. (2012). Genmab and Janssen Biotech enter worldwide license agreement for daratumumab.
